872-64-0

Basic information

• Product Name: 6-azaspiro[2.5]octane
• Synonyms: 6-azaspiro[2.5]octane
• CAS NO: 872-64-0
• Molecular Formula: C₇H₁₃N
• Molecular Weight: 111.18482
• Mol File: 872-64-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 59-60 °C(Press: 4 Torr)
• Appearance: /
• Density: 0.96±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.60±0.20(Predicted)
• CAS DataBase Reference: 6-azaspiro[2.5]octane(CAS DataBase Reference)
• NIST Chemistry Reference: 6-azaspiro[2.5]octane(872-64-0)
• EPA Substance Registry System: 6-azaspiro[2.5]octane(872-64-0)

Safety Data

• Hazardous Substances Data: 872-64-0(Hazardous Substances Data)

Usage

General Description

6-Azaspiro[2.5]octane, also known as azepane, is a saturated heterocyclic compound with a seven-membered ring containing one nitrogen atom. It is commonly used as a building block in organic synthesis and pharmaceuticals due to its stable and versatile structure. This chemical is often employed in the production of various drugs and agricultural chemicals, as well as in the creation of complex organic molecules. 6-Azaspiro[2.5]octane exhibits potential pharmacological activity and has been studied as a potential treatment for various medical conditions. Its unique ring structure and chemical properties make it a valuable and important component in the field of organic chemistry and drug research.

Upstream product

• 955028-67-8 tert-butyl 6-azaspiro[2.5]octane-6-carboxylate 

Downstream Products

• 1257396-70-5 2-{6-[6-azaspiro[2.5]oct-6-yl(4-fluorophenyl)methyl]-4'-(trifluoromethyl)biphenyl-3-yl}propanoic acid 

Relevant articles and documents

Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties

8-Nitrobenzothiazinones (BTZs) typified by the second-generation analogue PBTZ169 are a new class of antitubercular agents. The activity of BTZs and lipophilicity are tightly coupled since the molecular target DprE1 is located in the mycobacterial cell envelope. A series of analogues was designed to address the notorious insolubility of the BTZs while preserving the required lipophilicity. This was accomplished by decreasing the molecular planarity and symmetry through bioisosteric replacement of the piperazine moiety of PBTZ169 with spirocyclic and bicyclic diamines. Several promising compounds with improved aqueous solubilities were identified with potent antitubercular activity. Compound 5 was identified as the most promising candidate based on its excellent antitubercular activity (MIC of 32 nM), more than 1000-fold improvement in solubility, 2-fold lower clearance in mouse and human microsomes relative to PBTZ169, and promising pharmacokinetic parameters.